DOI: https://doi.org/10.25251/skin.4.5.0

Published: 2020-09-10

In-Depth Reviews

Topical Zinc May Augment Post-Operative Wound Healing, Including Following Mohs Micrographic Surgery: A Review of the Literature

Nicole Levin, Taylor Gray, Maheera Farsi, David Dorton, Richard Miller
| DOI https://doi.org/10.25251/skin.4.5.1

Page 395-403

PDF

Resident Competition Research Articles

Dermatologists' Perceptions and Use of Electronic Health Record Systems

Olivia Katamanin, Alex M Glazer MD
| DOI https://doi.org/10.25251/skin.4.5.2

Page 404-407

PDF

Management and Referral Patterns in Pediatric Atopic Dermatitis: A Survey of Pediatric Healthcare Professionals

Courtney Nicole Bernett, Emma Hignett, Pearl Kwong
| DOI https://doi.org/10.25251/skin.4.5.3

Page 408-416

PDF

The Impact of Skin Disease on Quality of Life in Rural Communities of Ghana

Caroline W Laggis, Aaron M Secrest, Martin Agyei, Sam Simister, Andrea N Davis, Ty Dickerson, Jamie LW Rhoads
| DOI https://doi.org/10.25251/skin.4.5.4

Page 417-423

PDF

Integrating Electrical Impedance Spectroscopy into Clinical Decisions for Pigmented Skin Lesions Improves Diagnostic Accuracy: A Multitiered Study

Graham H Litchman, Justin W Marson, Ryan M Svoboda, Darrel S Rigel
| DOI https://doi.org/10.25251/skin.4.5.5

Page 424-430

PDF

Sentinel Lymph Node Predictors in Melanoma of Breslow Thickness 0.8-1.0 mm

Luisa Fernanda Christensen, David Carr, Sheena Hill, Elizabeth Ramser, Jaime Abraham Perez, Jeremy Bordeaux
| DOI https://doi.org/10.25251/skin.4.5.6

Page 431-437

PDF

COVID Concepts

Maskne: Exacerbation or Eruption of Acne During the COVID-19 Pandemic

Tamar A Gomolin, Abigail Cline, Marian Russo
| DOI https://doi.org/10.25251/skin.4.5.7

Page 438-439

PDF

Chilblains-Like Lesions as a Presenting Manifestation of COVID-19

Victoria Comeau, Marcus Goodman, Carmen Julian, Francesca M Ceci
| DOI https://doi.org/10.25251/skin.4.5.8

Page 440-442

PDF

Brief Articles

Cetuximab Induced Hidrocystomas: A Case Report

Nicole Nagrani, David E Castillo, Mariya Miteva, Anna Nichols
| DOI https://doi.org/10.25251/skin.4.5.9

Page 443-445

PDF

Eruptive Oral Mucoceles in a Neonate

Ghassan Niaz, Ellen H de Moll, Lauren Zinns, Bryan Tassavor, Robert G Phelps
| DOI https://doi.org/10.25251/skin.4.5.10

Page 446-448

PDF

Blistering Rash over Broken Ribs

Kathleen R Graham, Bethany R Rohr, Victor J Marks
| DOI https://doi.org/10.25251/skin.4.5.11

Page 449-451

PDF

An Atypical Presentation of Pemphigus Vegetans in the Umbilicus

Antonio Jimenez, Paige Hoyer, Michael Wilkerson
| DOI https://doi.org/10.25251/skin.4.5.12

Page 452-455

PDF

Extensive Tinea Associated with Tofacitinib Therapy Masquerading as New-Onset SCLE

Connor R Buechler, Elena Kurland, Jesse Veenstra
| DOI https://doi.org/10.25251/skin.4.5.13

Page 456-459

PDF

Pilomatrical Carcinoma in a 70-Year-Old Hispanic Female

Jeffery S Harbold, Richard G Wagner, Rick Lin
| DOI https://doi.org/10.25251/skin.4.5.14

Page 460-463

PDF

A Rare Case of Angiolymphoid Hyperplasia without Eosinophils, with Review of the Literature

James Ko, Zachary P Nahmias, Patrick S Phelan, Sabra Abner, Kara Blackwell, Andras Schaffer
| DOI https://doi.org/10.25251/skin.4.5.15

Page 464-467

PDF

Facial Papules in Birt-Hogg-Dubé Syndrome: A Growing Spectrum of Pathologic Findings

Lauren G Yi, Ricardo Guerra, Sam B Wu, Richard H Flowers
| DOI https://doi.org/10.25251/skin.4.5.16

Page 468-471

PDF

A Postherpetic Isotopic Response Presenting as a Granuloma Annulare-Like Inflammatory Reaction

Haley D Heibel, Clay J Cockerell
| DOI https://doi.org/10.25251/skin.4.5.17

Page 472-475

PDF

Short Communications

Pruritic Papulonodules Following Tattoo Application

Carlos J Sarriera-Lazaro, Bijan Safai
| DOI https://doi.org/10.25251/skin.4.5.18

Page 476-477

PDF

Autosensitization due to Pediculosis Capitis (a “Pediculid”) in a 16-Year Old Female: A Case Report

Logan Kolb, Emma Hignett, Pearl Kwong
| DOI https://doi.org/10.25251/skin.4.5.19

Page 478-480

PDF

Compelling Comments

Delusions of Parasitosis Influenced by Crowdsourcing Diagnostic Platform CrowdMed

Julian Stashower, Katherine Belote, Barrett Zlotoff
| DOI https://doi.org/10.25251/skin.4.5.20

Page 481-482

PDF

Falling in Hair Love Comes Naturally

Emmanuella Oduguwa, Danyal Tahseen
| DOI https://doi.org/10.25251/skin.4.5.21

Page 483

PDF

Commentary & Notes

Plant Fiber Contaminants in Morgellons Disease Skin Samples

Marianne J Middelveen, Raphael B Stricker
| DOI https://doi.org/10.25251/skin.4.5.22

Page 484-485

PDF

Letter to the Editor: Commentary on “Avoiding the Hazards of Ultraviolet Light in the Adolescent Population”

Elise M Weisert, Ethan D Hinds III
| DOI https://doi.org/10.25251/skin.4.5.23

Page 486-487

PDF

Commentary in Response: Commentary on “Avoiding the Hazards of Ultraviolet Light in the Adolescent Population”

Alexander Auchus, Robert T Brodell, Vinayak K Nahar, Kimberley HM Ward
| DOI https://doi.org/10.25251/skin.4.5.24

Page 488

PDF

Dermatologic History

Norman Orentreich: Father of Hair Modern Transplantation

Michael Phan, Jonathan Phan
| DOI https://doi.org/10.25251/skin.4.5.25

Page 489-490

PDF

Poster Presentations from FCPANP20 Clinical Conference®: Psoriasis

An Oral, Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

Bruce Strober, Alice Gottlieb, Diamant Tha?i, Luis Puig, Matthew J Colombo, Sundeep Kundu, Renata Kisa, Subhashis Banerjee
| DOI https://doi.org/10.25251/skin.4.supp.27

Page s27

Poster PDF

BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients

Kenneth Gordon, Kim Papp, Melinda Gooderham, Akimichi Morita, Peter Foley, Diamant Tha?i, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banergee
| DOI https://doi.org/10.25251/skin.4.supp.28

Page s28

Poster PDF

BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI

Alice B Gottlieb, Bruce Strober, Diamant Tha?i, Kenneth Gordon, Sundeep Kundu, Renata Kisa, Lan Wei, Subhashis Banerjee, Joseph Merola
| DOI https://doi.org/10.25251/skin.4.supp.29

Page s29

Poster PDF

Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study

Mark Lebwohl, James Q Del Rosso, Chih-Ho Hong, Anna M Tailman, Leon Kircik
| DOI https://doi.org/10.25251/skin.4.supp.30

Page s30

Poster PDF

Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial

Mark Lebwohl, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie H M?rch, Diamant Tha?i, Richard B Warren
| DOI https://doi.org/10.25251/skin.4.supp.31

Page s31

Poster PDF

Long-Term Proactive Management of Psoriasis Vulgaris with Fixed-Dose Combination of Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam: Results from a Phase III Randomized Controlled Trial

Mark Lebwohl, Jean-Philippe Lacour, Monika Liljedahl, Charles Lynde, Marie H M?rch, Diamant Tha?i, Richard B Warren
| DOI https://doi.org/10.25251/skin.4.supp.32

Page s32

Poster PDF

Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis

Francisco Kerdel, Christina Don, Renata Block, Caitlin Lewis, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.4.supp.33

Page s33

Poster PDF

Combination of Calcipotriene 0.005% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis

Alexis Young, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.4.supp.34

Page s34

Poster PDF

A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis

Adelaide A Herbert, Debbie Glaab, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.4.supp.35

Page s35

Poster PDF

Phase 3 Trial Demonstrates that MC2-01 Cream has Improved Treatment Efficacy Compared to Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in Patients with Mild to Moderate Psoriasis Vulgaris

Johan Selmer, Birgitte Vestbjerg, Morten Pr?stegaard, Linda Stein Gold
| DOI https://doi.org/10.25251/skin.4.supp.36

Page s36

Poster PDF

Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients with Baseline Body Surface Area of 6 -12%

Linda Stein Gold, Jonathan S Weiss, Lawrence Green, Leon Kircik, Lauren Miller, Abby Jacobson, Susan Harris
| DOI https://doi.org/10.25251/skin.4.supp.37

Page s37

Poster PDF

Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study

Mark G Lebwohl, Jeffrey Sugarman, David M Pariser, Jerry Bagel, Cynthia Trickett, Abby Jacobson, Robert Israel
| DOI https://doi.org/10.25251/skin.4.supp.38

Page s38

Poster PDF

Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from Resurface 1 and Resurface 2

Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Jeffrey Parno, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads
| DOI https://doi.org/10.25251/skin.4.supp.39

Page s39

Poster PDF

Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in Resurface 1

Wendy Cantrell, Patricia Lee, Alan M Mendelsohn, Jeff Parno, Stephen J Rozzo, Wilson Liao
| DOI https://doi.org/10.25251/skin.4.supp.40

Page s40

Poster PDF

Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab

Kim A Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Jeff Parno, Alan M Mendelsohn, Melinda Gooderham
| DOI https://doi.org/10.25251/skin.4.supp.41

Page s41

Poster PDF

Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies

Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn
| DOI https://doi.org/10.25251/skin.4.supp.42

Page s42

Poster PDF

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab, a High-Affinity Anti–Interleukin-23P19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis

Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Alice B Gottlieb, Richard C Chou, Alan M Mendelsohn, Michael E Luggen
| DOI https://doi.org/10.25251/skin.4.supp.43

Page s43

Poster PDF

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, C Leonardi, Y Poulin, M Boehnlein, S Kavanagh, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.44

Page s44

Poster PDF

Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)

K Gordon, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.45

Page s45

Poster PDF

Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies

A Blauvelt, C Paul, P van de Kerkhof, R B Warren, A B Gottlieb, R G Langley, F Brock, C Arendt, M Boehnlein, M Lebwohl, K Reich
| DOI https://doi.org/10.25251/skin.4.supp.46

Page s46

Poster PDF

Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Stephen Tyring, Anna Tailman, April Armstrong
| DOI https://doi.org/10.25251/skin.4.supp.69

Page s47

Poster PDF

Atopic Dermatitis

Dupilumab Improves Symptoms of Anxiety and Depression in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Three Phase 3 Trials (LIBERTY AD SOLO 1 and 2 and ADOL)

Jonathan I Silverberg, Weily Soong, Benjamin Lockshin, Abhijit Gadkari, Zhen Chen, Ashish Bansal
| DOI https://doi.org/10.25251/skin.4.supp.47

Page s48

Poster PDF

Dupilumab Decreases Blood Biomarkers in Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From a Phase 3 Trial (LIBERTY AD ADOL)

Eric L Simpson, Hiroyuki Fujita, Kazuhiko Arima, Jennifer Hamilton, Yufang Lu, Ana B Rossi, Ashish Bansal
| DOI https://doi.org/10.25251/skin.4.supp.48

Page s49

Poster PDF

Long-Term Effect of Dupilumab With Concomitant Topical Corticosteroids on POEM in Adults With Moderate-to-Severe Atopic Dermatitis: LIBERTY AD CHRONOS Trial

Jonathan I Silverberg, Benjamin Lockshin, Melinda Gooderham, Zhen Chen, Abhijit Gadkan, Ana B Rossi
| DOI https://doi.org/10.25251/skin.4.supp.49

Page s50

Poster PDF

Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial (LIBERTY AD ADOL)

Lawrence Sher, Weily Soong, Randy Prescilla, Zhen Chen, Ashish Bansal
| DOI https://doi.org/10.25251/skin.4.supp.50

Page s51

Poster PDF

Acne & Rosacea

Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

Angela Moore, Suzanne Bruce, Neil Sadick, Eduardo Tschen, Philip Werschler, Sunil Dhawan, Douglas Farsha, Michael Gold, Scott Guenthner, Steve Kempers, Leon Kircik, Jennifer Parish, Marta Rendon, Phoebe Rich, Linda Stein-Gold, Stephen Tyring, Robert Weiss, Adnan Nasir, Carsten Schmitz, Terry Boodhoo, Alexandre Kaoukhov, David Berk, Fran Cook-Bolden, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.51

Page s52

Poster PDF

Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris

David M Pariser, Lawrence J Green, Edward L Lain, Carsten Schmitz, Amy S Chinigo, Brian McNames, David R Berk, Jamison Hoffman, Ayman Grada
| DOI https://doi.org/10.25251/skin.4.supp.52

Page s53

Poster PDF

Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea

Linda Stein Gold, James Q Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.53

Page s54

Poster PDF

Integrated Safety and Efficacy Analysis of FMX103 1.5% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea: Results From Two Phase 3 Studies

James Q Del Rosso, Linda Stein Gold, Leon Kircik, Neal D Bhatia, Neil Sadick, Matthew Zirwas, Edward Lain, Iain Stuart
| DOI https://doi.org/10.25251/skin.4.supp.54

Page s55

Poster PDF

Effect of Combination Therapy on Visible/Non-Visible Symptoms, and Disease Burden Associated with Severe Rosacea: Results from A Post-Hoc Analysis of A Randomized Controlled Trial

James Q Del Rosso, Mark Jackson, Sandra Johnson, Alison Harvey, Rajeev Chavda
| DOI https://doi.org/10.25251/skin.4.supp.55

Page s56

Poster PDF

Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study

Jerry Tan, James Del Rosso, Jonathan Weiss, Linda Stein Gold, Fran Cook-Bolden, Lawrence Eichenfeld, Emil Tanghetti, Alessandra Ali? Saenz, Faiz Ahmad
| DOI https://doi.org/10.25251/skin.4.supp.56

Page s57

Poster PDF

Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris

James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber
| DOI https://doi.org/10.25251/skin.4.supp.57

Page s58

Poster PDF

Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability

Linda Stein Gold, David M Pariser, Marci Levy, Eric Guenin
| DOI https://doi.org/10.25251/skin.4.supp.58

Page s59

Poster PDF

Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males With Moderate-to-Severe Acne

Hilary E Baldwin, Lawrence Green, Leon Kircik, Ashlie M Caronia, Eric Guenin
| DOI https://doi.org/10.25251/skin.4.supp.59

Page s60

Poster PDF

Nail Unit Disorders

Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients

Lawrence F Eichenfield, Boni Elewski, Jeffrey L Sugarman, Ted Rosen, Aditya Gupta, Wendy Cantrell, Radhakrishnan Pillai, Abby Jacobson
| DOI https://doi.org/10.25251/skin.4.supp.60

Page s61

Poster PDF

Dermatopharmacology

Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension

Morten Pr?stegaard, Birgitte Vestbjerg, Johan Selmer, Tove Holm-Larsen
| DOI https://doi.org/10.25251/skin.4.supp.61

Page s62

Poster PDF

Skin Cancer

Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies

Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce
| DOI https://doi.org/10.25251/skin.4.supp.62

Page s63

Poster PDF

Impact of a Prognostic 40-Gene Expression Profiling Test on Clinical Management Decisions for High-Risk Cutaneous Squamous Cell Carcinoma

Graham H Litchman, Alison L Fitzgerald, Sarah J Kurley, Robert W Cook, Darrell S Rigel
| DOI https://doi.org/10.25251/skin.4.supp.63

Page s64

Poster PDF

Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis

Scott Freeman, Miriam Bettencourt, Meg Corliss, Nikeshia Dunkelly-Allen, Karen A Veverka
| DOI https://doi.org/10.25251/skin.4.supp.64

Page s65

Poster PDF

Efficacy of ALA–PDT in the Treatment of Actinic Keratoses on the Upper Extremities: A Post Hoc Analysis of a Phase 3, Randomized, Vehicle-Controlled Trial

Brian Berman, Neal Bhatia, Daniel Piacquadio, Anna Houlihan, Daniel Siegel
| DOI https://doi.org/10.25251/skin.4.supp.65

Page s66

Poster PDF

Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study

Alexander Guminski, Nicholas Squittieri, John T Lear
| DOI https://doi.org/10.25251/skin.4.supp.66

Page s67

Poster PDF

Duration of Response and Progression-Free Survival with Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind

Michael Migden, John Lear, Nicholas Squittieri, Li Liu, Alexander Guminski, Reinhard Dummer
| DOI https://doi.org/10.25251/skin.4.supp.67

Page s68

Poster PDF

Effect of Concomitant Medications on Efficacy of Sonidegib 200 Mg Daily in Patients with Locally Advanced Basal Cell Carcinoma: Results of the 42-Month Randomized, Double-Blind BOLT Study

Richard Dummer, Michael Migden, Nicholas Squittieri, Li Liu, Alexander Guminski, John Lear
| DOI https://doi.org/10.25251/skin.4.supp.68

Page s69

Poster PDF